Braeburn Announces FDA Advisory Committee Recommends Approval of CAM2038 Buprenorphine Depot for the Treatment of Opioid Use Disorder

Braeburn today announced that the U.S. Food and Drug Administration’s (FDA) Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee jointly voted 17-3 recommending approval of CAM2038, an investigational buprenorphine weekly and monthly depot injection for the treatment of adults with opioid use disorder (OUD).

Braeburn Participates in President’s Commission Meeting on Combating Drug Addiction and the Opioid Crisis

Braeburn today participated in the Third Meeting of the President’s Commission on Combating Drug Addiction and the Opioid Crisis. Braeburn President and CEO, Mike Derkacz shared the Company’s progress in advancing new, long-acting treatment options to help address the escalating disease burden of addiction faced by Americans, including the development of injectable treatments for opioid use disorder (OUD) to potentially minimize the risk of diversion and abuse.